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To the Editor 
Since 1954, whole brain radiation therapy (WBRT) has been an integral palliative treatment modality for 
brain metastases
1
.  For over 40 years, the standard palliative WBRT regimen in the United States has 
been 30 Gy in 10 fractions over two weeks, although shorter regimens have been reported
2-4
.  While 
prolonged (≥10 fractions) WBRT regimens have historically been favored due to a perceived 
improvement in neurocognitive side effect profile, hypofractionated WBRT is equally effective for 
disease control
2,3
 and reduces the burden of prolonged treatment on patients and caregivers near the 
end of life. Additionally, some patients cannot finish planned WBRT due to declining performance status 
(PS); however, the likelihood of failing to complete standard-fractionation WBRT has not been rigorously 
evaluated. To address this void, the following analysis was performed to allow for improved objective 
quantifying of this commonly utilized palliative modality. 
Methods 
An IRB-approved prospective institutional database identified 52 patients receiving WBRT (30 Gy/10 
fractions) for brain metastases between April 2015-December 2018. Functional independence was 
defined as Karnofsky PS (KPS) >70; 30-day mortality was defined as death within 30 days immediately 
after final radiation treatment. Statistical analyses were performed in SPSS v.24 (IBM Corp., Armonk, 
NY).  P<0.05 was considered statistically significant. 
Results 
Of 52 patients who began WBRT, 29 (55.8%) completed prescribed therapy; demographics are depicted 
in Table 1. Patients completing WBRT were significantly more likely to be functionally independent at 
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baseline and had lower 30-day mortality.  Mean treatment duration for patients completing WBRT was 
15.3 days. Of the 23 patients failing to complete standard WBRT, 30-day mortality was nearly 70%.  
 
Discussion 
Brain metastases carry a poor prognosis; median survival following WBRT is 3-4 months
2,3,5
.  However, 
this relatively long anticipated survival following WBRT has historically provided practitioners with 
confidence that prolonged treatment regimens will not adversely affect QOL.  Our results indicate this 
widespread presumption may be incorrect. The large minority (nearly 50%) of patients prescribed 
standard ten-fraction WBRT who died without completing treatment suggests that a large subset of this 
patient population may not live as long as generally presumed. Consequently, adjustments to clinical 
practice of both prescribing and requesting WBRT should be considered, particularly since the data 
originally establishing ten-fraction WBRT as the standard of care demonstrated no significant difference 
in survival or local control between 30 Gy in ten fractions, 20 Gy in five fractions, or 10 Gy in one 
fraction2-3.  Additionally, Level I evidence has demonstrated no neurocognitive advantage of prolonged 
WBRT
6
. For the significant proportion of WBRT patients with <4 weeks to live, any reduction in 
treatment time represents a meaningful reduction in the rigors of daily traveling for a treatment that 
confers no survival advantage over shorter schedules. 
Furthermore, the modern WBRT patient population is likely enriched for poor-KPS patients and those 
with a larger disease burden, as more favorable patients (i.e., those with oligometastatic disease) are 
increasingly likely to receive stereotactic radiosurgery instead.  Median survival following WBRT in the 
modern era may therefore actually be shorter compared with historical data collected before 
stereotactic radiosurgery was considered standard of care for good KPS patients with 1-3 brain 
metastases.  
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Limitations of this study include its small sample size, retrospective nature, and single-institution source 
of data, each of which independently limit the scope of our conclusions.  However, the relative 
standardization of WBRT practice increases the applicability of our findings.  
 
Conclusions 
Over 40% of patients prescribed standard ten-fraction WBRT regimens are unable to tolerate the full 
duration of treatment.  With nearly half of patients dying within 30 days of standard 10-fraction WBRT, 
hypofractionated (i.e., 1- or 5-fraction) regimens may reduce the physical and financial burden of 
treatment on this population and should be strongly considered by clinicians, especially in poor-
performance status patients. 
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Table 1: Clinical characteristics of patients who did vs. did not complete WBRT. 
 
Patient 
Demographic 
Failed WBRT Completion 
(n = 23) 
Completed WBRT  
(n = 29) 
P value 
Age (mean) 58.0 58.2 0.966 
    
Male  11 (47.8%) 11 (37.9%) 0.576 
Female 12 (52.2%) 18 (62.1%)  
    
Inpatient 14 (60.1%) 12 (41.4%) 0.264 
Outpatient 9 (29.9%) 17 (58.6%)  
    
KPS > 70 4 (17.4%) 13 (44.8%) 0.043 
    
Death within 30 
days of final fraction 
16 (69.6%) 9 (31.0%) 0.011 
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